The case for & against
Bull & Bear analysis
Bearish
IGM Biosciences, Inc. (NASDAQ: IGMS) was a clinical-stage biotechnology company focused on developing engineered immunoglobulin M (IgM) antibodies to treat a variety of cancers and autoimmune diseases. The company's pipeline included bispecific antibodies and potential therapies targeting various oncology applications. However, the company is no longer publicly traded following its acquisition by Concentra Biosciences in August 2025.
Bull says
- ↑Cash and investments of $427.2M fund operations into H2 2024
- ↑Imvodimab targets autoimmune diseases with high unmet medical needs
- ↑IgM-8444 combination trial shows favorable safety and clinical activity
- ↑Planned IND filings for lupus and RA candidates expand pipeline
- ↑Innovative IgM antibody platform offers differentiation vs established therapies
- ↑Solid financial health underpins growth strategy in oncology and immunotherapy
Bear says
- ↓FY 2022 net loss of $221.1M ($5.32/share) reflects high burn rate
- ↓2023 operating expenses guidance of $290–300M pressures cash runway
- ↓Regulatory and IND filing uncertainties may delay pipeline progress
- ↓Competitive pressures from BMY, ABBV, and PFE challenge market entry
- ↓Clinical trial execution risk: failure to improve PFS could derail
- ↓Elevated R&D spend ($179.3M in 2022) intensifies liquidity concerns
Investment themes with IGMS
Biotech↑ +0.07%
Genetic and drug innovations driving medical breakthroughs
ABBV · AMGN · TMO
Hi Short Interest↑ +1.03%
Stocks with high short interest ratios
BYND · PLTR · COIN
Earnings Call · Q4 2020 · Mgmt. Guidance
Updated 09-09-2026neutral
Transcript signals
Bull points
- we are very excited about the prospects for IgM 7354, our targeted IL-15 immune cell stimulating antibody, as well as our broader pipeline.
- Overall, we believe we are well on our way to demonstrating a best-in-class safety profile.
- We are very encouraged by the fact that to date we have not had a case of CRS beyond grade one except in that very small subset of patients who had both prior CAR T treatment and circulating B cells at baseline.
Bear points
- Our net loss for the fourth quarter of 2020 was $24.6 million, or a loss of 79 cents per share.
- For the full year 2020, our net loss was $81.4 million, or a loss of $2.65 per share.
- we expect our full year 2021 GAAP operating expenses to be between $175 million and $185 million.
Read full transcript analysis ›